Log in
NASDAQ:OBLN

Obalon Therapeutics Stock Forecast, Price & News

$0.91
+0.03 (+3.41 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.86
Now: $0.91
$0.92
50-Day Range
$0.68
MA: $0.79
$0.99
52-Week Range
$0.62
Now: $0.91
$2.35
Volume202,311 shs
Average Volume410,243 shs
Market Capitalization$7.04 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.83
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Read More
Obalon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
CUSIPN/A
Phone844-362-2566

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.28 million
Book Value$2.06 per share

Profitability

Net Income$-23,680,000.00
Net Margins-694.12%

Miscellaneous

Employees100
Market Cap$7.04 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$0.91
+0.03 (+3.41 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

How has Obalon Therapeutics' stock been impacted by Coronavirus?

Obalon Therapeutics' stock was trading at $1.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OBLN stock has decreased by 12.5% and is now trading at $0.91.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Obalon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Obalon Therapeutics
.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Obalon Therapeutics
.

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) announced its quarterly earnings results on Thursday, July, 30th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.24. The business had revenue of $0.70 million for the quarter. Obalon Therapeutics had a negative return on equity of 133.43% and a negative net margin of 694.12%.
View Obalon Therapeutics' earnings history
.

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Are investors shorting Obalon Therapeutics?

Obalon Therapeutics saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 330,400 shares, a decrease of 11.2% from the August 15th total of 372,000 shares. Based on an average daily trading volume, of 377,100 shares, the short-interest ratio is presently 0.9 days.
View Obalon Therapeutics' Short Interest
.

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Opko Health (OPK), Vaxart (VXRT), Inpixon (INPX), Actinium Pharmaceuticals (ATNM), Co-Diagnostics (CODX), NIO (NIO), Novavax (NVAX) and Onconova Therapeutics (ONTX).

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the following people:
  • Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
  • Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 57)
  • Ms. Daina Schmidt, VP of Marketing

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $0.91.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $7.04 million and generates $3.28 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is www.obalon.com.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.